MedPath

Effect of Ciprofol on Intraoperative Hypotension in Elderly Patients Receiving Renin-angiotensin System Inhibitors

Phase 4
Recruiting
Conditions
Intraoperative Hypotension
Ciprofol
Renin-angiotensin System Inhibitors
Interventions
Registration Number
NCT06952608
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Brief Summary

The prevention of intraoperative hypotension could reduce postoperative organ injury and mortality, particularly in elderly patients receiving long-term renin-angiotensin system inhibitors. Previous meta-analyses suggest that ciprofol, a novel intravenous anesthetic agent, may provide improved hemodynamic stability compared to propofol; however, its precise effects on perioperative hemodynamics remain unclear. The study will assess whether ciprofol improves perioperative hemodynamic stability in elderly patients receiving renin-angiotensin system inhibitors.

Detailed Description

Elderly patients receiving long-term renin-angiotensin system inhibitors commonly exhibit reduced vascular elasticity, impaired cardiovascular reserve, and diminished compensatory mechanisms. Regular use of renin-angiotensin system inhibitors has thus emerged as a significant risk factor for intraoperative hypotension, increasing the potential for end-organ injury and closely correlating with postoperative complications such as myocardial injury, acute kidney injury, and increased mortality.

Ciprofol (HSK3486) is a novel intravenous anesthetic agent that has demonstrated efficacy non-inferior to propofol for induction and maintenance of general anesthesia, with an improved safety profile and fewer adverse effects. Recent meta-analyses indicate that ciprofol administration is associated with a significantly reduced incidence of intraoperative hypotension compared with propofol; however, robust evidence from randomized controlled trials (RCTs) remains limited. The present study aims to evaluate the impact of ciprofol on perioperative hemodynamics in elderly patients receiving renin-angiotensin system inhibitors. Given the increased risk of intraoperative hypotension in this patient cohort, the investigation of hemodynamic stability with ciprofol holds substantial clinical significance and may inform anesthetic management strategies for this vulnerable population.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
140
Inclusion Criteria
  1. Patients undergoing elective abdominal surgery under general anesthesia
  2. Duration of surgery exceeding 2 hours
  3. Patients receiving long-term renin-angiotensin system inhibitor therapy (>3 months prior to surgery)
  4. Age ≥ 65 years
  5. ASA classification II-III
  6. Informed consent was obtained from patients or their guardians
Exclusion Criteria
  1. History of allergy to opioids, propofol, or ciprofol components.

  2. Anticipated difficult airway (limited mouth opening, restricted neck movement, or modified Mallampati grade III-IV) or difficult mask ventilation.

    Body mass index ≤18 or ≥35 kg/m².

  3. Severe hepatic dysfunction (total bilirubin ≥3.0 mg/dL or AST/ALT ≥2 times the upper limit of normal).

  4. Severe renal impairment (creatinine clearance ≤30 mL/min).

  5. Cardiac diseases (AV block higher than first-degree, heart rate <50 bpm, severe arrhythmias, severe valvular heart disease, heart failure, or unstable angina on the day of surgery).

  6. Preoperative cognitive impairment, cerebrovascular disease, or history of psychiatric illness.

  7. Abnormal thyroid-stimulating hormone levels or history of thyroid replacement therapy.

  8. Unstable asthma or history of asthma.

  9. Alcohol abuse, drug abuse, chronic opioid dependence, or analgesic use exceeding 3 months.

  10. Lactating or pregnant women.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ciprofol GroupCiprofol groupGeneral anesthesia induction and maintenance were performed using ciprofol.
Propofol groupPropofol groupGeneral anesthesia induction and maintenance were performed using propofol.
Primary Outcome Measures
NameTimeMethod
The time-weighted average of hypotensionFrom the beginning to the end of the surgery

The time-weighted average is measured by calculating the area under the threshold (AUT) divided by the total duration of surgery

Secondary Outcome Measures
NameTimeMethod
Changes in Cerebral Oxygen Saturation (rSO₂)Intraoperative
Incidence of perioperative major adverse cardiovascular and cerebrovascular eventsPeriprocedural
Changes in Stroke Volume Variation (SVV)Intraoperative

Nomal value:≤10%,and higher scores mean a worse outcome.

Changes in Cardiac Index (CI)Intraoperative

Nomal value:2.5-4.0 L/min/m²,and values outside the normal range suggest worse clinical outcomes

Time-weighted average of hypotensionwithin 15 minutes after induction of anesthesia

The time-weighted average is measured by calculating the area under the threshold (AUT) divided by the total duration of induction.

Incidence of intraoperative hypotensionFrom the beginning to the end of the surgery
Dosage of vasoactive drugsFrom the beginning to the end of the surgery
Success rate of general anesthesia inductionFrom the beginning to the end of the surgery

MOAA/S score of 1 or less after administration of ciprofol or propofol, 1 or fewer top-up doses, and no use of rescue drug

Proportion of intraoperative time with BIS ≤ 60From the beginning to the end of the surgery
Total dosage of ciprofol and propofolFrom the beginning to the end of the surgery
Total dosage of rescue drugsFrom start of drug administration to MOAA/S ≤1 (up to 5 minutes)
Time to extubationPerioperative
Incidence of intraoperative adverse eventsFrom the beginning to the end of the surgery
Incidence of adverse events in the PACUduring the PACU stay
Changes in Systemic Vascular Resistance Index (SVRI)Intraoperative

Nomal value :1970-2390 dyn·s·cm-⁵·m²,and values outside the normal range suggest worse clinical outcomes

Trial Locations

Locations (1)

The Second Affiliated Hospital of Zhejiang University anesthesiology department

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath